Good products shape the new frontiers of knowledge. Please visit our booth #1938 at #DDW2024 to explore our latest innovations.
#ColonCancerAwarenessMonth Did you know that the majority of cancer in situ is found in small and diminutive polyps rather than large ones? Studies show 68.67% vs. 31.33%, emphasizing the importance of detecting and removing all polyps for effective defense against colon cancer.
Join us at #USCAP2024 in Baltimore, MD, March 23-28. Visit booth #858 for our innovative lymph node metastasis detection system, advanced 3D tumor analysis, & automated CRC/HGD, LGD, benign lesion classification in colon cancer screening.
Introducing the Future of Histology: Groundbreaking 3D Viewer Unveiled to Reveal Tumor Spatial Characteristics newswire.com/news/introducin…
🔬 Explore with us at the Annual Meeting of the College of American Pathologists in Chicago! 🌟 Visit Booth #119 to discover the unique technology approach from Wision. Find out how our innovations may impact clinical practice. 🌐#CAP23 #AI #3Dpathology
Wision A.I. retweeted
@NMansourMD shows why AI may be the standard of care in CRC. Surrounded by legends in the field of CRC screening #DDW2023 WAY TO GO
If CADe contributes to finding more polyps, it should have capabilities under difficult scenarios, see how EndoScreener performs. youtube.com/playlist?list=PL…
#DDW #ArtificialIntelligence
EndoScreener software uses deep learning A.I. and CADe to analyze and detect local abnormalities in the colon, improving standard colonoscopy's detection and precision.
For more information, please visit @MicroTechEndo Booth #4516.
youtu.be/AMH8vl7bKr0
#DDW2023 #Chicago
Wision A.I. retweeted
Micro-Tech Endoscopy is excited to be exhibiting at @ASGEendoscopy AI Primer Workshop on Friday May 5, from 1-5 pm at the Hyatt Regency McCormick Place in #Chicago. #DDW2023
Wision A.I. retweeted
EndoScreener® software uses deep learning A.I. and CADe to analyze and detect local abnormalities in the colon, improving standard colonoscopy's detection and precision. To arrange an evaluation contact CustomerCare at hubs.ly/Q01JpcZP0 or call 877.552.4027
We are thrilled to announce that EndoScreener obtained the first Class III approval from National Medical Products Administration (“NMPA”) in China！Excited to have the opportunity to serve patients worldwide with improved preventative screening that EndoScreener offers!
We are grateful that Micro-Tech Endoscopy will help us to make this technology generally available in the U.S. #DDW2022 #AI
businesswire.com/news/home/2…
We are grateful that Micro-Tech Endoscopy will help us to make this technology generally available in the U.S. #DDW2022 #AI
businesswire.com/news/home/2…
▶️2020, First US-based RCT of AI polyp detection completed. cghjournal.org/article/S1542…
The EndoScreener algorithm was specifically engineered with small data (5545 images), so it does not "converge" with other devices as the data grows. Small data requires less labeling work and less computational expenditure, and therefore, lower costs. nature.com/articles/s41551-0…
*Very* important question. My belief is that #AI / #computervision tech is advanced enough that most polyp detection tools will converge at 'very high performance'. Differentiating factors will include turn-key integration, user interface, product support, cost...
Wision A.I. Expands U.S. Offerings to Combat Colorectal Cancer With Multiple Screening Tools globenewswire.com/en/news-re…
Cost is not an issue now since we have the 510K clearance.
Congrats to all involved on this *critical* study. GI Genius results align w/ CADeT-CS RCT led by @jglissenbrown using Wision AI device (bit.ly/3IcmK96).
We are on track to demonstrate that #AI during screening colo = gold standard approach. Cost remains key barrier.
Wision A.I. Achieves CE-MDR Mark Approval for AI-assisted Diagnostic Software Medical Device Supporting Colonoscopy prn.to/3DhZbdm
Appreciate the tremendous efforts of all the investigators on this landmark trial.
1/ Harvard research foregrounds AI as colonoscopy tool news.harvard.edu/gazette/sto… via @Harvard
